APA (7th ed.) Citation

SA, W., M, S., M, S., MÁ, B., EM, C., D, R., . . . HM, K. (2024). A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(1), 74. https://doi.org/10.1158/1078-0432.CCR-23-0475

Chicago Style (17th ed.) Citation

SA, Weiss, et al. "A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 30, no. 1 (2024): 74. https://doi.org/10.1158/1078-0432.CCR-23-0475.

MLA (9th ed.) Citation

SA, Weiss, et al. "A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 30, no. 1, 2024, p. 74, https://doi.org/10.1158/1078-0432.CCR-23-0475.